Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06368635

The Cerebral Microcirculation Diseases and Coronary Microcirculation Disease Study

The Cerebral Microcirculation Diseases and Coronary Microcirculation Disease Study(CCMD)

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Weijing Wang · Other Government
Sex
All
Age
45 Years – 80 Years
Healthy volunteers

Summary

Ischaemic heart disease (IHD) and degenerative brain disease are two major sources of death and disability affecting all countries. While the consequences of obstructive disease in major vessels supplying blood to both organs have been widely documented, less attention has been paid to disease processes affecting the microcirculation that may affect cardiac and cerebral function. Yet, over the last decade significant progress has been made in understanding the substrate of microvascular disease in both organs. In the heart, arteriolar thickening and capillary rarefaction that reduce the conductance of the microvasculature and its ability to vasodilate in response to increased myocardial oxygen demands constitute the leading cause of coronary microvascular dysfunction (CMD). In the brain, concentric hyaline thickening of deep penetrating small arteries (arteriolosclerosis) with associated fibrosis of the vessel wall constitutes the most frequent substrate for cerebral small vessel disease (CSVD). Of note, both CMD and CSVD share common risk factors, such as age, hypertension, and diabetes.3 These factors might have a common effect on the microvascular domain of cardiac and cerebral vascular beds. Although a potential link between both conditions has been hypothesized based on the similarities between pathological changes and risk factors, advance in knowledge exploring this has been hampered by lacking objective evidence of CMD and pathological brain changes indicative of CSVD in prior research studies. Thus, the relationship between CMD and CSVD is unknown. The main objective of this study was to analyse the relationship between cerebrovascular disease and CMD in patients with atherosclerotic coronary artery disease (CAD).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCoronary angiographytarget vessel with intermediate coronary lesion (40-80% diameter stenosis and FFR(fractional flow reserve) ≥0.8; or severe stenosis(\>80%)after successful PCI(percutaneous coronary intervention) and FFR ≥0.8

Timeline

Start date
2024-01-01
Primary completion
2024-12-31
Completion
2025-03-31
First posted
2024-04-16
Last updated
2024-04-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06368635. Inclusion in this directory is not an endorsement.